explore -WSS

explore

author：entertainment 2025-09-29 22:53:50 - browse：53663

Sterile capsules for injection line up in a dispensing line — politics coverage from STAT — Adobe

WASHINGTON — The Senate Finance Committee has drafted a bipartisan bill to mitigate drug shortages by rewarding hospitals for business practices that ensure an adequate supply of drugs.

Drug shortages have been a persistent problem for years, and they’re worse than ever, according to a recent report by the American Society of Health-System Pharmacists. Shortages are primarily a problem for hospitals and doctors who regularly administer drugs, including oncologists who have been running out of common chemo drugs. Generic injectables account for 67% of shortages, and more than half of drugs in short supply cost less than $1 per unit, according to the Finance Committee.

Hospitals band together to negotiate drug prices by hiring group purchasing organizations. The biggest three GPOs are estimated to control about 90% of the market for drugs that hospitals buy. Finance Chair Ron Wyden (D-Ore.) said those GPOs can drive prices down so low that manufacturers stop making certain drugs or can’t afford to maintain their facilities, which then leads to manufacturing interruptions. Drugmakers also say GPOs can also be fickle, switching from one manufacturer to another over small savings, leaving drugmakers without the certainty they need to commit to making large volumes of product.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： STAT letters to the editor on burnt

focus

WSS

Antibody drugs appear effective. Now can we make enough of them?

Is there an 'orca uprising'? Like orcas themselves, the answer is complex.

What PEPFAR has meant on the ground in Ukraine

Watch the official trailer for 'Ahsoka' series

Cuban government calls US nuclear submarine stop a 'provocative escalation'

Supreme Court wrestles with OxyContin maker's bankruptcy deal

focus

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

explore

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

One Duchenne patient's bittersweet hope for new treatment

Medical leaders decry Supreme Court decision on affirmative action

Roche to buy Carmot Therapeutics, developer of obesity drugs

Alkermes shareholders re

How are insurers handling Leqembi and related scans?

Hepatitis C has a cure — but many Americans still lack access to it

Pfizer plans to depart BIO

Novavax promises a turnaround & Lilly roils the obesity market

Iran's president begins a rare visit to Africa 'to promote economic diplomacy'

leisure time

Spinal cord stimulation reduces pain in amputees, study finds

Patients' immediate access to test results puts radiologists in a bind

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Americans' trust in science, scientist continues decline: Report

AI models in health care face new federal disclosure requirements

focus

focus

focus

entertainment